bioRxivCancer BiologyPreprint
DOTA chelation through click chemistry enables favorable biodistribution of 89Zr-radiolabeled antibodies: A comparison with DFO chelation
R. Imura, Y. Kumakura, L. Yan, Y. Shimoura, H. Takahashi, H. Ida, Y. Wada, N. Akimitsu
Abstract
Currently, the DFO chelator is commonly used to conjugate monoclonal antibodies (mAbs) and 89Zr, whereas the DOTA chelator is commonly used to conjugate mAbs and alpha- and beta-emitting metal radionuclides. However, if the degradation of [89Zr]Zr-DFO-mAb is not negligible, the in vivo biodistribution of 89Zr might not reflect that of metal radionuclides conjugated with DOTA-mAb. We hypothesized that [89Zr]Zr-DOTA-mAb as a new imaging counterpart would accurately predict the biodistribution of therapeutic metal radionuclides delivered by DOTA-mAb. In this study, we prepared [89Zr]Zr-DOTA-trastuzumab for the first time by a two-step reaction using click chemistry and then investigated the differences in biodistribution profiles between two chelating approaches for 89Zr. MethodsWe prepared [89Zr]Zr-DOTA-trastuzumab from DOTA-tetrazine conjugates (DOTA-Tz) and transcyclooctene-trastuzumab conjugates (TCO-trastuzumab). We first radiolabeled DOTA-Tz with 89Zr in a reaction solution of MeOH and HEPES buffer and then used a click reaction to obtain [89Zr]Zr-DOTA-Tz/TCO-trastuzumab. We performed biodistribution studies and PET imaging with [89Zr]Zr-DOTA-trastuzumab in a mouse model of HER2-positive ovarian cancer, SKOV3 xenograft mice at 24, 72, and 144 hours post-injection and compared these data with those of [89Zr]Zr-DFO-trastuzumab. ResultsTCO-trastuzumab was radiolabeled with [89Zr]Zr-DOTA-Tz in the two-step reaction in good radiochemical yield (57.8 {+/-} 17.6%). HER2-positive tumors were clearly visualized with [89Zr]Zr-DOTA-trastuzumab in PET imaging studies. The temporal profile changes of 89Zr radioactivity in SKOV3 tumors and bone marrow were sufficiently different between [89Zr]Zr-DOTA-trastuzumab and [89Zr]Zr-DFO-trastuzumab (P View larger version (30K): org.highwire.dtl.DTLVardef@d7256borg.highwire.dtl.DTLVardef@d9d3d5org.highwire.dtl.DTLVardef@e24d97org.highwire.dtl.DTLVardef@1541bf0_HPS_FORMAT_FIGEXP M_FIG C_FIG
- organism: mouse
- assay: imaging
- research focus: drug response / drug discovery
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Click-to-Release: Cleavable Radioimmunoimaging with 89Zr-DFO-Trans-Cyclooctene-Trastuzumab Increases Tumor-to-Blood Ratio
M. Vlastara, R. Rossin, … M. S. Robillard·bioRxiv·Mar 27, 2023
- Feasibility of real-time in vivo 89Zr-DFO-labeled CAR T-cell trafficking using PET imaging
- A translatable evaluation tool to study the biodistribution of clinically-available doxorubicin liposomes: PET imaging of Zr-Talidox
Amaia Carrascal-Miniño, Aishwarya Mishra, … Rafael T. M. de Rosales·bioRxiv·Jun 17, 2025
- A general approach to reduce off-target radioactivity in vivo via Tetrazine-Knock-Out (TKO)
Swarbhanu Sarkar, Jonathan M. Pham, … Mark A. Sellmyer·bioRxiv·May 30, 2024
- Comparable daughter radionuclide redistribution with superior tumor absorbed dose of the SSTR2 antagonist Ac-DOTA-TATE
Prachi Bharat Desai, Marion Huber, … Anika Jaekel·bioRxiv·Mar 18, 2026
- Mathematical Modeling Unveils Optimization Strategies for Targeted Radionuclide Therapy of Blood Cancers
Maxim Borisovich Kuznetsov, Vikram Adhikarla, … Russell C. Rockne·Cancer Research CommunicationsPeer-reviewed·Oct 28, 2024